Frontiers of Medicine

, Volume 11, Issue 2, pp 287–292 | Cite as

Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases

  • Xinping Zhou
  • Juying Wei
  • Yinjun Lou
  • Gaixiang Xu
  • Min Yang
  • Hui Liu
  • Liping Mao
  • Hongyan Tong
  • Jie Jin
Case Report


Castleman disease (CD) is uncommon non-clonal lymphoproliferative disorder with unknown etiology. No standard therapy is recommended for relapsed/refractory CD patients, thus requiring development of novel experimental approaches. Our cohort of three adult patients with multicentric CD (MCD) were treated with refractory to traditional chemotherapy lenalidomide-containing regimens (10–25 mg lenalidomide perorally administered on days 1–21 in 28-day cycle) as second- to fourth-line treatment. Partial remission was achieved in first plasma-cell CD patient, who relapsed seven months after autologous hematopoietic stem cell transplantation and then failed to respond to four cycles of chemotherapy. Partial remission was obtained in second patient with CD and polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome. Third case showed complete remission with complete disappearance of pleural effusion and ascites and normalization of platelet count. To conclude, encouraging clinical responses were achieved in cohort of three patients with lenalidomide-based regimen, though long-term efficacy remains to be observed.We propose further investigation of therapeutic potential of this drug in treating MCD.


Castleman disease lenalidomide 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



We are thankful to Dr. Liang Zou, member of Department of Pathology of the First Affiliated Hospital, College of Medicine, Zhejiang University for provision of pathological images.


  1. 1.
    Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of Castleman disease. Cancer Control 2014; 21(4): 266–278CrossRefPubMedGoogle Scholar
  2. 2.
    Ye B, Gao SG, Li W, Yang LH, Zhao SH, Ma K, Zhu XL, Liu XY, Sun KL. A retrospective study of unicentric and multicentric Castleman’s disease: a report of 52 patients. Med Oncol 2010; 27 (4): 1171–1178CrossRefPubMedGoogle Scholar
  3. 3.
    Bower M, Newsom-Davis T, Naresh K, Merchant S, Lee B, Gazzard B, Stebbing J, Nelson M. Clinical features and outcome in HIVassociated multicentric Castleman’s disease. J Clin Oncol 2011; 29 (18): 2481–2486CrossRefPubMedGoogle Scholar
  4. 4.
    Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Madelaine-Chambrin I, Boulanger E, Chevret S, Agbalika F, Oksenhendler E. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007; 25(22): 3350–3356CrossRefPubMedGoogle Scholar
  5. 5.
    Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A, Fisher M, Nelson M, Gazzard B, Stebbing J, Kelleher P. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007; 147(12): 836–839CrossRefPubMedGoogle Scholar
  6. 6.
    Hoffmann C, Schmid H, Müller M, Teutsch C, van Lunzen J, Esser S, Wolf T, Wyen C, Sabranski M, Horst HA, Reuter S, Vogel M, Jäger H, Bogner J, Arasteh K. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 2011; 118(13): 3499–3503CrossRefPubMedGoogle Scholar
  7. 7.
    Marcelin AG, Aaron L, Mateus C, Gyan E, Gorin I, Viard JP, Calvez V, Dupin N. Rituximab therapy for HIV-associated Castleman disease. Blood 2003; 102(8): 2786–2788CrossRefPubMedGoogle Scholar
  8. 8.
    Marrache F, Larroche C, Mémain N, Bouchaud O, Robineau M, Hermine O, Lortholary O. Prolonged remission of HIV-associated multicentric Castelman’s disease with an anti-CD20 monoclonal antibody as primary therapy. AIDS 2003; 17(9): 1409–1410CrossRefPubMedGoogle Scholar
  9. 9.
    Powles T, Stebbing J, Montoto S, Nelson M, Gazzard B, Orkin C, Webb A, Bower M. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood 2007; 110(12): 4132–4133CrossRefPubMedGoogle Scholar
  10. 10.
    Nicoli P, Familiari U, Bosa M, Allice T, Mete F, Morotti A, Cilloni D, Saglio G, Guerrasio A. HHV8-positive, HIV-negative multicentric Castleman’s disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. Int J Hematol 2009; 90(3): 392–396CrossRefPubMedGoogle Scholar
  11. 11.
    Law AB, Ryan G, Lade S, Prince HM. Development of Kaposi’s sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient. Int J Hematol 2010; 91(2): 347–348CrossRefPubMedGoogle Scholar
  12. 12.
    Ide M, Kawachi Y, Izumi Y, Kasagi K, Ogino T. Long-term remission in HIV-negative patients with multicentric Castleman’s disease using rituximab. Eur J Haematol 2006; 76(2): 119–123CrossRefPubMedGoogle Scholar
  13. 13.
    Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013; 19(13): 3659–3670CrossRefPubMedGoogle Scholar
  14. 14.
    Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106(8): 2627–2632CrossRefPubMedGoogle Scholar
  15. 15.
    Nagao A, Nakazawa S, Hanabusa H. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases. J Hematol Oncol 2014; 7(1): 10CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Adam Z, Szturz P, Křen L, Krejčí M, Pour L, Svoboda T, Hanke I, Penka I, Koukalová R, Rehák Z, Cervinková I, Storková T, Král Z, Mayer J. PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview. Vnitr Lek 2013; 59(4): 301–312 (in Czech)PubMedGoogle Scholar
  17. 17.
    Zhao X, Shi R, Jin X, Zheng J. Diffuse hyperpigmented plaques as cutaneous manifestation of multicentric Castleman disease and treatment with thalidomide: report of three cases. J Am Acad Dermatol 2011; 65(2): 430–432CrossRefPubMedGoogle Scholar
  18. 18.
    Ramasamy K, Gandhi S, Tenant-Flowers M, Ceesay M, Corderoy S, Marcus R, Schey S. Rituximab and thalidomide combination therapy for Castleman disease. Br J Haematol 2012; 158(3): 421–423CrossRefPubMedGoogle Scholar
  19. 19.
    Ghosh N, Grunwald MR, Fasan O, Bhutani M. Expanding role of lenalidomide in hematologic malignancies. Cancer Manag Res 2015; 7: 105–119CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Tomás JF, Giraldo P, Lecumberri R, Nistal S. POEMS syndrome with severe neurological damage clinically recovered with lenalidomide. Haematologica 2012; 97(2): 320–322CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Szturz P, Adam Z, Chovancová J, Stehlíková O, Klabusay M, Rehák Z, Koukalová R, Krejčí M, Pour L, Zahradová L, Hájek R, Mayer J. Lenalidomide: a new treatment option for Castleman disease. Leuk Lymphoma 2012; 53(10): 2089–2091CrossRefPubMedGoogle Scholar
  22. 22.
    Szturz P, Adam Z, Rehak Z, Koukalova R, Kren L, Moulis M, Krejcí M, Mayer J. Salvage lenalidomide in four rare oncological diseases. Tumori 2013; 99(5): e251–e256CrossRefPubMedGoogle Scholar
  23. 23.
    Szturz P, Adam Z, Rehák Z, Koukalová R, Sprláková-Puková A, Michalka J, Smardová L, Volfová P, Lengerová M, Mayer J. Castleman disease: retrospective single-center study of therapeutic results in 10 patients. Klin Onkol 2013; 26(2): 124–134 (in Czech)CrossRefPubMedGoogle Scholar
  24. 24.
    Chu BF, Shana’ah A, Hofmeister CC, Benson DM, Sell M, Tucker J, Pichiorri F, Efebera YA. Long-term therapy with lenalidomide in a patient with POEMS syndrome. Eur J Case Rep Intern Med 2014; 1: 2014_000093PubMedPubMedCentralGoogle Scholar
  25. 25.
    Dispenzieri A. POEMS syndrome: update on diagnosis, riskstratification, and management. Am J Hematol 2015; 90(10): 951–962CrossRefPubMedGoogle Scholar
  26. 26.
    Dispenzieri A, Klein CJ, Mauermann ML. Lenalidomide therapy in a patient with POEMS syndrome. Blood 2007; 110(3): 1075–1076CrossRefPubMedGoogle Scholar
  27. 27.
    Royer B, Merlusca L, Abraham J, Musset L, Haroche J, Choquet S, Leleu X, Sebban C, Decaux O, Galicier L, Roussel M, Recher C, Banos A, Guichard I, Brisseau JM, Godmer P, Hermine O, Deplanque G, Facon T, Asli B, Leblond V, Fermand JP, Marolleau JP, Jaccard A. Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. Am J Hematol 2013; 88(3): 207–212CrossRefPubMedGoogle Scholar
  28. 28.
    Zagouri F, Kastritis E, Gavriatopoulou M, Sergentanis TN, Psaltopoulou T, Terpos E, Dimopoulos MA. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Leuk Lymphoma 2014; 55(9): 2018–2023CrossRefPubMedGoogle Scholar
  29. 29.
    Yuan ZG, Dun XY, Li YH, Hou J. Treatment of multicentric Castleman’s disease accompanying multiple myeloma with bortezomib: a case report. J Hematol Oncol 2009; 2(1): 19CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol 2016; 9(1): 52CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gupta N, Goh YT, Min CK, Lee JH, Kim K, Wong RS, Chim CS, Hanley MJ, Yang H, Venkatakrishnan K, Hui AM, Esseltine DL, Chng WJ. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. J Hematol Oncol 2015; 8(1): 103CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Zhou N, Huang CW, Huang C, Liao W. The characterization and management of Castleman’s disease. J Int Med Res 2012; 40(4): 1580–1588CrossRefPubMedGoogle Scholar
  33. 33.
    Lin Q, Fang B, Huang H, Yu F, Chai X, Zhang Y, Zhou J, Xia Q, Li Y, Song Y. Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman’s disease. Blood Cancer J 2015; 5(3): e298CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Xinping Zhou
    • 1
  • Juying Wei
    • 1
  • Yinjun Lou
    • 1
  • Gaixiang Xu
    • 1
  • Min Yang
    • 1
  • Hui Liu
    • 1
  • Liping Mao
    • 1
  • Hongyan Tong
    • 1
  • Jie Jin
    • 1
  1. 1.Department of Hematology, the First Affiliated Hospital, College of MedicineZhejiang UniversityHangzhouChina

Personalised recommendations